{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Angi, Inc. Stock Plummets to New 52-Week Low of $7.18
Angi, Inc. has reached a new 52-week low, reflecting a significant decline over the past year, contrasting with broader market performance. Despite this, the company shows resilience with a notable one-year performance increase. However, it faces challenges related to management efficiency and modest operating profit growth.
Angi, Inc. Stock Plummets to New 52-Week Low of $7.37
Angi, Inc. has reached a new 52-week low, reflecting a significant decline over the past year. Despite a strong one-year performance, the company's financial metrics raise concerns, including low management efficiency and modest operating profit growth. Angi's market capitalization stands at USD 394 million amid a competitive landscape.
Angi, Inc. Stock Plummets to New 52-Week Low of $7.63
Angi, Inc. has hit a new 52-week low, reflecting significant challenges over the past year with a notable decline in stock performance. The company has a market capitalization of USD 394 million, a low price-to-book ratio, and manageable debt levels, while institutional holdings have slightly increased.
Is Angi, Inc. overvalued or undervalued?
As of November 28, 2025, Angi, Inc. is considered overvalued with a P/E ratio of 16, a Price to Book Value of 0.81, and an EV to EBITDA of 8.45, especially when compared to peers like GoodRx Holdings, Inc. at 31.76 and eGain Corp. at 6.67, suggesting it may not be a compelling investment.
Is Angi, Inc. overvalued or undervalued?
As of November 28, 2025, Angi, Inc. is considered overvalued with a P/E ratio of 16, an EV to EBITDA ratio of 8.45, and a Price to Book Value of 0.81, indicating it is less attractive compared to peers like GoodRx Holdings, Inc. with a P/E of 31.76.
Is Angi, Inc. overvalued or undervalued?
As of November 7, 2025, Angi, Inc. is fairly valued with a P/E ratio of 16, a Price to Book Value of 0.81, and an EV to EBITDA of 8.45, making it more attractive than peers like Sharecare, Inc. and GoodRx Holdings, Inc.
Is Angi, Inc. overvalued or undervalued?
As of November 7, 2025, Angi, Inc. is fairly valued with a P/E ratio of 16, a Price to Book Value of 0.81, and an EV to EBITDA of 8.45, showing more attractiveness compared to peers and indicating significant growth potential.
Is Angi, Inc. technically bullish or bearish?
As of October 24, 2025, Angi, Inc. shows a mildly bearish technical trend, with mixed signals from MACD and Bollinger Bands across different time frames, despite some short-term strength indicated by daily moving averages.
Is Angi, Inc. technically bullish or bearish?
As of October 24, 2025, Angi, Inc. shows a mildly bearish trend overall, with weekly indicators predominantly bearish despite some mildly bullish signals on the daily timeframe.
Is Angi, Inc. technically bullish or bearish?
As of October 24, 2025, Angi, Inc. shows a mildly bearish technical trend, with bearish signals from the weekly MACD and Bollinger Bands, despite a mildly bullish monthly MACD and daily moving averages.
Is Angi, Inc. overvalued or undervalued?
As of October 17, 2025, Angi, Inc. is considered fairly valued with a P/E ratio of 16, a Price to Book Value of 0.81, and an EV to EBITDA of 8.45, positioning it competitively against peers like GoodRx and eGain.
Is Angi, Inc. overvalued or undervalued?
As of October 17, 2025, Angi, Inc. is rated as attractive with a P/E ratio of 16, an EV to EBITDA ratio of 8.45, and a Price to Book Value of 0.81, indicating it is fairly valued and potentially undervalued compared to peers like GoodRx Holdings, Inc. and eGain Corp.
Is Angi, Inc. overvalued or undervalued?
As of October 17, 2025, Angi, Inc. is considered attractive and undervalued with a P/E ratio of 16, a price to book value of 0.81, and an EV to EBITDA ratio of 8.45, indicating it trades at a discount compared to peers like GoodRx Holdings, Inc. and eGain Corp.
Is Angi, Inc. overvalued or undervalued?
As of October 10, 2025, Angi, Inc. is considered very attractive and undervalued, with a P/E ratio of 16, an EV to EBITDA of 8.45, and a low PEG ratio of 0.01, making it more appealing compared to peers like GoodRx Holdings, Inc. and EverQuote, Inc.
Is Angi, Inc. technically bullish or bearish?
As of August 26, 2025, Angi, Inc. shows a mildly bullish technical trend supported by positive MACD and moving averages, despite mixed signals from KST and Bollinger Bands.
Is Angi, Inc. overvalued or undervalued?
As of September 3, 2025, Angi, Inc. is considered undervalued with an attractive valuation grade, supported by favorable metrics such as a P/E ratio of 16 and a Price to Book Value of 0.81, especially when compared to peers like GoodRx Holdings, Inc. at 31.76.
Is Angi, Inc. overvalued or undervalued?
As of May 22, 2025, Angi, Inc. is considered an attractive investment due to its undervalued status, with a P/E ratio of 16, a Price to Book Value of 0.81, and an EV to EBITDA of 8.45, all indicating it trades below its intrinsic value compared to peers like EverQuote, Inc.
Is Angi, Inc. technically bullish or bearish?
As of June 11, 2025, Angi, Inc. has shifted to a mildly bearish trend, indicated by daily moving averages and mixed monthly signals, despite some mildly bullish weekly indicators.
Who are in the management team of Angi, Inc.?
As of March 2022, the management team of Angi, Inc. includes Chairman Joseph Levin, CEO William Ridenour, Interim CFO Glenn Schiffman, and several directors: Kendall Handler, Craig Smith, Mark Stein, Suzy Welch, and Gregg Winiarski. They oversee the company's operations and strategic direction.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
